Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study-Reference-Cited by-同舟云学术

Identification of factors that may influence the selection of first‐line biological therapy for people with psoriasis: a prospective, multicentre cohort study

Published:2017-07-26 Issue:3 Volume:177 Page:828-836
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Davison N.J.¹²^ORCID,Warren R.B.³,Mason K.J.²,McElhone K.²,Kirby B.⁴,Burden A.D.⁵,Smith C.H.⁶,Payne K.¹,Griffiths C.E.M.³

Affiliation:

1. Manchester Centre for Health Economics The University of Manchester Manchester U.K.

2. BADBIR (on behalf of the PSORT consortium) The University of Manchester Manchester U.K.

3. The Dermatology Centre Salford Royal NHS Foundation Trust The University of Manchester Manchester Academic Health Science Centre Manchester U.K.

4. Department of Dermatology St Vincent's University Hospital Dublin Ireland

5. Department of Dermatology Western Infirmary Glasgow U.K.

6. St John's Institute of Dermatology Guy's and St Thomas’ NHS Foundation Trust London U.K.

Funder

Medical Research Council

University of Manchester

British Association of Dermatologists

Pfizer

AbbVie

Novartis

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.15551

Reference33 articles.

1. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence

2. National Institute for Health and Care Excellence.Psoriasis: assessment and management. Clinical guideline [CG153]. Available at:https://www.nice.org.uk/guidance/cg153(last accessed 24 June 2017).

3. National Institute for Health and Care Excellence.Secukinumab for treating moderate to severe plaque psoriasis. Technology appraisal guidance [TA350]. Available at:https://www.nice.org.uk/guidance/ta350(last accessed 24 June 2017).

4. National Institute for Health and Care Excellence.Ixekizumab for treating moderate to severe plaque psoriasis. Technology appraisal guidance [TA442]. Available at:https://www.nice.org.uk/guidance/ta442(last accessed 24 June 2017).

5. Establishing an Academic–Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of disease registers in dermatology;British Journal of Dermatology;2024-01-04

2. Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study;Acta Dermato-Venereologica;2023-03-09

3. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis;JAMA Dermatology;2021-09-01

4. Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase;Journal of Investigative Dermatology;2021-08

5. Functional analysis of generalized linear models under non-linear constraints with applications to identifying highly-cited papers;Journal of Informetrics;2021-02